We use cookies to ensure that our site works correctly and provides you with the best experience. If you continue using our site without changing your browser settings, we'll assume that you agree to our use of cookies. Find out more about the cookies we use and how to manage them by reading our cookies policy.
European contract pharma development and manufacturing organisation (CDMO), 3P Biopharmaceuticals has signed a collaboration agreement with Australian biotech Ondek for the production of an immunotherapy based on the Helicobacter pylori organism.